Glucotrack Files Definitive Proxy Statement

Ticker: GCTK · Form: DEF 14A · Filed: Aug 19, 2024 · CIK: 1506983

Glucotrack, INC. DEF 14A Filing Summary
FieldDetail
CompanyGlucotrack, INC. (GCTK)
Form TypeDEF 14A
Filed DateAug 19, 2024
Risk Levellow
Pages16
Reading Time19 min
Key Dollar Amounts$4,000,000, $25,000, $0.001, $5.00, $1.875
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, regulatory-filing, corporate-governance

TL;DR

Glucotrack filed its proxy statement, standard shareholder stuff.

AI Summary

Glucotrack, Inc. filed a Definitive Proxy Statement (DEF 14A) on August 19, 2024. This filing is related to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company, formerly known as Integrity Applications, Inc., is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing is a standard regulatory requirement for public companies, indicating that Glucotrack is preparing for or has held shareholder-related activities requiring formal communication and voting.

Risk Assessment

Risk Level: low — This is a routine regulatory filing and does not inherently present new risks to investors.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a DEF 14A filing?

A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxy votes from shareholders for annual or special meetings. It contains important information about matters to be voted on, director nominees, executive compensation, and other corporate governance details.

When was Glucotrack, Inc. formerly known as Integrity Applications, Inc.?

Glucotrack, Inc. was formerly known as Integrity Applications, Inc. until December 3, 2010.

What is Glucotrack, Inc.'s fiscal year end?

Glucotrack, Inc.'s fiscal year ends on December 31.

What is the SIC code for Glucotrack, Inc.?

The Standard Industrial Classification (SIC) code for Glucotrack, Inc. is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.

Where is Glucotrack, Inc. located?

Glucotrack, Inc.'s business and mailing address is 301 RT 17 NORTH, SUITE 800, RUTHERFORD, NJ 07070.

Filing Stats: 4,768 words · 19 min read · ~16 pages · Grade level 12.1 · Accepted 2024-08-19 17:22:33

Key Financial Figures

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 5 PROPOSAL 1: PROPOSAL TO APPROVE, FOR PURPOSES OF COMPLYING WITH NASDAQ LISTING RULE 5635(b), THE FULL ISSUANCE OF SHARES OF COMMON STOCK ISSUABLE BY THE COMPANY UPON CONVERSION OF THE NOTE AND THE WARRANTS 6 PROPOSAL 2: ADJOURNMENT PROPOSAL 9 HOUSEHOLDING 10 STOCKHOLDER PROPOSALS 10 GLUCOTRACK, INC. PROXY FOR THE SPECIAL MEETING OF STOCKHOLDERS To Be Held on September 24, 2024 The following information is furnished to each stockholder in connection with the foregoing Notice of Special Meeting of Stockholders of Glucotrack, Inc., a Delaware corporation, to be held exclusively online via the Internet on September 24, 2024, at 11:00 a.m. (Eastern time) at https://www.virtualshareholdermeeting.com/GCTK2024 SM . The enclosed proxy is for use at the special meeting of stockholders (the “Special Meeting”) and any postponement or adjournment thereof. Unless the context requires otherwise, references to “Glucotrack,” “the Company,” “we,” “our,” and “us” in this Proxy Statement refer to Glucotrack, Inc. In accordance with the bylaws of the Company (as they may be amended, supplemented or otherwise modified from time to time, the “Bylaws”), the Special Meeting has been called for the following purposes: 1. To approve, for purposes of complying with Nasdaq Listing Rule 5635(b), the full issuance of shares of common stock issuable by the Company upon conversion of the Note (as defined below) and exercise of the Warrants (as defined below) (the “Issuance Proposal”); 2. To adopt and approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if it is determined by the Company that more time is necessary or appropriate to approve the Issuance Proposal at the Special Meeting (the “Adjournment Propo

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing